SecBot SecBot
SECBOTREPLAY Home › Report › SPRO

SPRO · Spero Therapeutics reported a significant turnaround in financial…

Spero Therapeutics, Inc. · PRESS-RELEASE filed Mar 26, 2026 at 16:05 ET

At the news

BULLISHIMPACT 8/10

PRESS-RELEASE filed Mar 26, 2026 at 16:05 ET

Spero Therapeutics reported a significant turnaround in financial performance for Q4 and full-year 2025, driven by a 177% YoY revenue increase to $41.3M in the quarter, primarily from collaboration payments with GSK and Pfizer, while R&D expenses dropped 80% due to reduced trial activity. The company also announced that the FDA set a PDUFA date of June 18, 2026, for tebipenem HBr, an investigational oral antibiotic for cUTI, with cash reserves of $40.3M expected to fund operations into 2028.

  • Net income of $31.5M in Q4 2025 vs. net loss of $(20.9)M in Q4 2024
  • Total revenue of $41.3M in Q4 2025, up from $15.0M in Q4 2024 (175% YoY growth)
  • Full-year 2025 revenue of $66.8M vs. $48.0M in 2024
  • R&D expenses fell to $5.6M in Q4 2025 from $28.8M in Q4 2024 due to completion of the PIVOT-PO trial

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access